Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Felbamate (compound)

Name: felbamate
PubChem Compound ID: 10562608
Molecular formula: C11H14N2O4
Molecular weight: 250.195 g/mol
Name: felbamate
Name (isomeric): DB00949
Drug Type: small molecule
Brand: Felbamyl, Felbatol, Taloxa
Category: Antiepileptic Agents, Neuroprotective Agents, Anticonvulsants
CAS number: 25451-15-4
Indication: For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
Felbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-80...
show more »
Mechanism of Action:
The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-reco...
show more »
Absorption: >90%
Protein binding: 20-36%
Biotransformation: Hepatic
Half Life: 20-23 hours
Clearance: 26 +/- 3 mL/hr/kg [single 1200 mg dose] 30 +/- 8 mL/hr/kg [multiple daily doses of 3600 mg]
Toxicity: LD50=5000 mg/kg (Orally in rats)
Affected organisms: Humans and other mammals
Food interaction:
Taking it after a meal may reduce the incidence of adverse effects.
Drug interaction:
MephenytoinIncreased phenytoin levels and decreased felbamate levels
PhenytoinIncreased phenytoin levels and decreased felbamate levels
TriprolidineThe CNS depressants, Triprolidine and Felbamate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Divalproex sodiumFelbamate increases the effect of valproate
QuinupristinThis combination presents an increased risk of toxicity
show more »